Page last updated: 2024-08-16

temozolomide and xl765

temozolomide has been researched along with xl765 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H1
Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY1

Trials

1 trial(s) available for temozolomide and xl765

ArticleYear
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Neuro-oncology, 2015, Volume: 17, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome

2015

Other Studies

1 other study(ies) available for temozolomide and xl765

ArticleYear
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Endocrinology, 2013, Volume: 154, Issue:3

    Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2013